- Wall Street indices open more or less flat
- US500 tests 50-session moving average
- Viking Therapeutics surges 17% after Q2 earnings
- Edward Lifesciences slumps 25% after Q2 earnings
Wall Street indices launched today's cash session more or less flat compared to yesterday's closing levels. S&P 500, Dow Jones and Nasdaq opened 0.05-0.10% higher, while small-cap Russell 2000 added 0.3% at session launch. This comes after yesterday's steep sell-off triggered by disappointing earnings releases from Alphabet and Tesla.
US GDP report released earlier today turned out to be a positive surprise, with annualized growth accelerating from 1.4% in Q1 2024 to 2.8% in Q2 2024, while analysts expected an acceleration to 2.0%. While the report triggered an uptick on US index futures, it was not enough to trigger a large move. Traders are weighing solid data from the US economy against risk of smaller or slower easing from Fed.
Start investing today or test a free demo
Open real account TRY DEMO Download mobile app Download mobile app
Source: xStation5
Wall Street indices are not allowed to catch a breath after yesterday's sell-off, with major US benchmarks failing to launch a recovery move. Taking a look at S&P 500 futures chart (US500) at D1 interval, we can see the index trade lower today, but the magnitude of the move is nowhere near that from yesterday. Index is making a break below the 50-session moving average (green line) today. However, according to Overbalance methodology, as long as the price stays above 5,350 pts area, where the lower limit of market geometry and 23.6% retracement can be found, the main trend remains bullish.
Company News
Viking Therapeutics (VKTX.US) launched today's cash session with a big bullish price gap, following release of Q2 earnings report. Company reported a $0.20 loss per share, less than $0.27 loss expected by analysts and slightly more than $0.19 loss reported a year ago. Drug developer is still in early-stage and continues to report $0 quarterly revenue. However, company said that its weight-loss drug advanced to late-stage trials and it is driving a spike in Viking's share price.
ServiceNow (NOW.US) jumped at the launch of today's cash trading, responding to Q2 earnings release. Company reported adjusted revenue at $2.64 billion (exp. $2.61 billion), with subscription revenue reaching $2.54 billion (exp. $2.53 billion). Adjusted gross profit of $2.17 billion also turned out to be higher than $2.15 billion expected. Remaining performance obligation was reported at $18.6 billion (exp. $17.6 billion), while current performance obligation was reported at $8.78 billion (exp. $8.68 billion). Company expects Q3 subscription revenue at $2.66-2.67 billion (exp. $2.68), while full-year forecast calls for 2024 subscription revenue of $10.58-10.59 billion, up from previous guidance of $10.56-10.58 billion.
Viking Therapeutics (VKTX.US) launched today's trading with a big bullish price gap. Stock rallies after Q2 earnings releases and is trading around 17% higher on the day. Bulls are now testing $60 resistance zone. Source: xStation5
West Pharmaceutical Services (WST.US) takes a hit after cutting full-year forecasts. Company reported 6.9% YoY drop in Q2 net sales to $702.1 million (exp. $729.3 million), with Proprietary Products net sales dropping 9.4% YoY to $559.7 million (exp. $592.8 million). Organic sales were 5.9% YoY lower. Adjusted operating income plunged 32% YoY to $126.4 million (exp. $155.1 million) and adjusted EPS was reported at $1.52, lower than $1.74 expected and $2.11 reported a year ago. Company lowered full-year net sales forecast from $3.00-3.03 billion to $2.87-2.90 billion) and adjusted EPS forecast from $7.63-7.88 to $6.35-6.65.
Edwards Lifesciences (EW.US) slumped after reporting a big miss in Q2 revenue. Company reported 9.4% YoY drop in revenue to $1.39 billion (exp. $1.65 billion). However, gross margin unexpectedly improved from 77.6% a year ago to 79.4% now (exp. 76.6%). Adjusted EPS of $0.70 also turned out to be higher than $0.66 reported a year ago and $0.69 expected by analysts for this quarter. Company expects Q3 sales to reach $1.56-1.64 billion (exp. $1.62 billion) while Q3 adjusted EPS is seen at $0.67-0.71 (exp. $0.69).
Edwards Lifesciences (EW.US) slumped after big Q2 sales miss. Company launched today's trading around 25% lower and trades at the lowest levels since November 2023. Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
